Skip to main content
Delfa

← Trials/Trial dossier/NCT00051909

CompletedPhase 2

Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease

Asset

LY451395

Listed sites

9

Recruiting sites

-

Enrollment

200

Study population

Alzheimer’s disease

Key I/E criteria

•Alzheimer's disease•Study partner/caregiver required

Primary endpoint

-

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study ID6764
SecondaryH6N-MC-LEAM
NCT IDNCT00051909

Timeline

Milestones

Study start2002-11 (month precision)
Study first posted2003-01-20estimated
Study completion2003-06 (month precision)
Last update posted2006-07-19estimated

Assets

Drug assets

LY451395

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age50 Years
SexAll
Healthy volunteersAccepted

Inclusion criteria

•Must have a clinical diagnosis of Alzheimer's Disease
•Must be at least 50 years of age
•Must fluently read and speak English
•Must have a reliable caregiver

Exclusion criteria

•Has serious health problems other than Alzheimer's Disease
•Cannot swallow whole pills
•Has had a menstrual period in the last two years
•Takes insulin for diabetes
•Has taken Aricept, Reminyl, or Exelon in the last 5 weeks

Endpoints (0)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

No endpoints recorded for this trial.

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 21, 2026
Endpoint classificationDelfa ADRD endpoint taxonomy
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.